Ben Hargreaves finds that a new line of attack could be the development of more effective non-opioid painkillers, with one potential therapy moving closer to approval. The opioid epidemic in the ...

agonist in phase 1 testing that also has potential as a non-opioid painkiller. Lilly's Zepbound has become the first drug approved by the FDA for obese patients with obstructive sleep apnoea ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but showed ...

Vertex Pharmaceuticals (NASDAQ:VRTX) just hit a major roadblock. The biotech heavyweight's much-anticipated non-opioid ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a ...

A 2017 study recommends rotating through classes of opioids, staying on the lowest possible dosage, and combining opioids with non-opioid painkillers. Titrating (building up) to higher doses slowly ...

The market for non-opioid painkillers is booming in the wake of a devastating overdose crisis and an opioid industry far ...

The Ministry of Food and Drug Safety announced on the 12th that it has granted item approval for Anapra (generic name: Opiranzeline), a non-narcotic pain reliever developed by Bicon Pharma.

Remember when someone lost their fake teeth at The Big E? Or when a horse had to be rescued after falling through a barn ...

The new combination, dubbed Alyftrek, is designed to improve on the Trikafta, a product that generated sales of $8.9 billion ...